Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Pulmonary Edema II: Pathophysiology01:18

Pulmonary Edema II: Pathophysiology

Pulmonary edema is the accumulation of fluid in the interstitial and alveolar spaces of the lungs, impairing gas exchange and oxygen delivery. It may be cardiogenic or noncardiogenic, but both reduce oxygenation and lung compliance.Cardiogenic Pulmonary EdemaCardiogenic edema results from increased hydrostatic pressure in pulmonary capillaries, usually due to left ventricular dysfunction from myocardial infarction, heart failure, or valvular disease. Ineffective cardiac pumping causes blood to...
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Origin, Niche, and State: A Three-Body Problem in Lung Macrophage Biology.

American journal of respiratory and critical care medicine·2026
Same author

Association Between Chronic PM2.5 Exposure and CT-Detected Lung Abnormalities in the SPIROMICS Cohort.

Annals of the American Thoracic Society·2026
Same author

Lung-Targeted HGF mRNA Restores Alveolar Structure in Experimental Emphysema.

The European respiratory journal·2026
Same author

Food Insecurity is Associated with COPD Prevalence and Mortality: Evidence from U.S. County-Level Data.

Annals of the American Thoracic Society·2026
Same author

Blood cell ratio biomarkers of systemic inflammation in chronic obstructive pulmonary disease.

Respiratory research·2026
Same author

Mapping the trajectory from pre-COPD to COPD: predictive value of symptoms, imaging, and physiologic abnormalities.

Annals of the American Thoracic Society·2026

Related Experiment Video

Updated: May 10, 2026

In Vivo Assessment of Alveolar Macrophage Efferocytosis Following Ozone Exposure
08:54

In Vivo Assessment of Alveolar Macrophage Efferocytosis Following Ozone Exposure

Published on: October 22, 2019

Efferocytosis and lung disease.

Alexandra L McCubbrey1, Jeffrey L Curtis2

  • 1Graduate Program in Immunology, VA Ann Arbor Healthcare System, Ann Arbor, MI.

Chest
|June 5, 2013
PubMed
Summary

Efficient clearance of apoptotic cells (efferocytosis) is crucial for tissue repair and preventing inflammation. Impaired efferocytosis in chronic lung diseases may worsen inflammation, suggesting therapies to enhance this process could be beneficial.

More Related Videos

Quantification of Efferocytosis by Single-cell Fluorescence Microscopy
06:15

Quantification of Efferocytosis by Single-cell Fluorescence Microscopy

Published on: August 18, 2018

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity
07:13

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

Related Experiment Videos

Last Updated: May 10, 2026

In Vivo Assessment of Alveolar Macrophage Efferocytosis Following Ozone Exposure
08:54

In Vivo Assessment of Alveolar Macrophage Efferocytosis Following Ozone Exposure

Published on: October 22, 2019

Quantification of Efferocytosis by Single-cell Fluorescence Microscopy
06:15

Quantification of Efferocytosis by Single-cell Fluorescence Microscopy

Published on: August 18, 2018

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity
07:13

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

Area of Science:

  • Immunology
  • Cell Biology
  • Pulmonology

Background:

  • Apoptosis is a daily process in healthy individuals, requiring efficient clearance by macrophages via efferocytosis.
  • Impaired efferocytosis and increased apoptotic cells are observed in chronic lung diseases like COPD, asthma, and cystic fibrosis.
  • This suggests a potential causal link between poor apoptotic cell clearance and persistent lung inflammation.

Purpose of the Study:

  • To review the literature on efferocytosis in chronic lung diseases.
  • To explore how existing therapies might enhance efferocytosis.
  • To discuss the potential benefits and risks of developing novel efferocytosis-augmenting therapies.

Main Methods:

  • Literature review of English-language scientific publications from 2006 to mid-2012.
  • Analysis of the role of efferocytosis in healthy individuals and in chronic airways diseases.
  • Examination of the mechanisms by which corticosteroids, statins, and macrolides may affect efferocytosis.

Main Results:

  • Alveolar macrophages in chronic lung disease patients exhibit reduced efferocytic capacity compared to healthy individuals.
  • Existing therapies like corticosteroids, statins, and macrolides may partially work by improving apoptotic cell clearance.
  • Enhanced efferocytosis, while beneficial for inflammation, could potentially compromise host defense against lung infections.

Conclusions:

  • Impaired efferocytosis is a significant factor in the sustained inflammation seen in chronic lung diseases.
  • Therapies aimed at enhancing efferocytosis show promise but require careful consideration due to potential impacts on host defense.
  • Personalized therapeutic strategies are needed to target specific disease phenotypes and optimize efferocytosis modulation for chronic lung conditions.